Started in 2017, Eikonizo Therapeutics has led an uphill battle to getting funding for its pipeline that includes drugs for ALS and Alzheimer’s, among other neurodegenerative diseases.

This unlikely CEO’s experience offers some valuable lessons in founding and scaling up a biotech company, particularly one in a nascent space such as regenerative medicine.

Adaptive Phage Therapeutics has created a large catalog of bacteria-killing viruses combined with a diagnostic test to identify and target specific bacterial strains infecting individual patients.

“The other part of being a CEO of a listed company is all about investors, and that was an uphill learning curve for me because I’d never dealt with that aspect,” explains Imugene’s CEO Leslie Chong.

In developing a new drug for MPN diseases, Imago is entering a space where two potential competitors, Jakafi and Inrebic, both JAK (janus associated kinase) inhibitors, are already on the market.

Scynexis is creating multiple development programs and a new class of antifungals — all in a single, and singular, drug.

With input from two long-time observers of the biopharma industry and its U.S. regulator, this article covers a cross-section of opinions regarding trends and proposals for improving the FDA review process.

What can make a company decide to enter new therapeutic entities into clinical development after decades as a dedicated supplier to bio research labs? Here we explain the reasons and implications of ArunA Bio’s decision.

Pluristem offers one example of how a new company in drug development can build the needed infrastructure to maintain its independence as a sponsor.

Obsidian Therapeutics targets gene and cell therapies with a technology designed to control the production and activity of therapeutic proteins those therapies induce.

This month’s company to watch is eXIthera, which is focused on inhibiting Factor XIa, a new target that may offer a way to avoid the bleeding problems with current anticoagulants.

Leading Biosciences is applying the science of digestive proteases to treating or preventing multiple diseases and conditions, starting with delayed return of post-surgical bowel function (ileus) and adhesion with its lead product candidate, coded LB1148.

One company is atypical in the industry for its use of patient and caregiver input to guide its drug-development journey. That shows in the program for its lead drug entering later-stage trials in treating Alzheimer’s disease.

The story of the business challenges faced by Diasome Pharmaceuticals as it develops its insulin-enhancing delivery technology, which seeks to correct a long-known deficiency in subcutaneous injection of insulin.